Seaport Global Advisors’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-3,742
Closed -$845K 96
2023
Q3
$845K Buy
3,742
+1,197
+47% +$276K 2.54% 8
2023
Q2
$562K Buy
2,545
+438
+21% +$97K 1.65% 15
2023
Q1
$472K Buy
2,107
+162
+8% +$39.9K 1.49% 16
2022
Q4
$541K Buy
1,945
+1,270
+188% +$321K 1.88% 8
2022
Q3
$141K Buy
675
+127
+23% +$28.4K 0.58% 79
2022
Q2
$129K Buy
+548
New +$111K 0.48% 97

Other funds holding UTHR

Seaport Global Advisors's UTHR Position: Q4 2023 in Review

Seaport Global Advisors sold out of United Therapeutics (UTHR) in Q4 2023, closing a stake of 3,742 shares — an estimated $845K sold.

Seaport Global Advisors first reported a position in UTHR in Q2 2022 and held it in 6 quarters. The position peaked at $845K in Q3 2023. 535 funds tracked by Wall St. Rank hold UTHR as of Q4 2023.

  • Seaport Global Advisors reported no remaining United Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Seaport Global Advisors sold 3,742 United Therapeutics shares in Q4 2023, an estimated $845K.
  • Seaport Global Advisors first reported a position in United Therapeutics in Q2 2022 and held it in 6 quarters.
  • Seaport Global Advisors's United Therapeutics position peaked at $845K in Q3 2023.
  • 535 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2023.

Based on Seaport Global Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.